Modulation of inflammatory mediators in the trigeminal ganglion by botulinum neurotoxin type A: an organ culture study by Jacob Edvinsson et al.
RESEARCH ARTICLE Open Access
Modulation of inflammatory mediators in
the trigeminal ganglion by botulinum
neurotoxin type A: an organ culture study
Jacob Edvinsson1, Karin Warfvinge1,2* and Lars Edvinsson1
Abstract
Background: Onabotulinumtoxin type A (BoNT-A) has been found to reduce pain in chronic migraine. The aim of
the present study was to ask if BoNT-A can interact directly on sensory mechanisms in the trigeminal ganglion (TG)
using an organ culture method.
Methods: To induce inflammation, rat TGs were incubated for 24 hrs with either the mitogen MEK1/2 inhibitor
U0126, BoNT-A or NaCl. After this the TGs were prepared for immunohistochemistry. Sections of the TG were
then incubated with primary antibodies against CGRP (neuronal transmitter), iNOS (inflammatory marker), IL-1β
(Interleukin 1β), SNAP-25 (synaptic vesicle docking protein) or SV2-A (Botulinum toxin receptor element).
Results: We report that CGRP, iNOS, IL-1β, SNAP-25 and SV2-A were observed in fresh TG with a differential
distribution. Interestingly, NaCl organ culture of the TG resulted in enhanced expression of CGRP and SNAP-25 in
neurons and iNOS in SGCs. Co-incubation with U0126 or BoNT-A retained the increased expression of SNAP-25,
while it decreased the IL-1β immunoreactivity in neurons. The iNOS expression in SGCs returned to levels observed
in fresh specimens. Moreover, we observed no alteration SV2-A expression in SGCs. Thus, the overall picture is that
both U0126 and BoNT-A have the ability to modify the expression of certain molecules in the TG.
Conclusion: We hypothesize that chronic migraine might be associated with some degree of inflammation in the
TG that could involve both neurons and SGCs. It is clinically well recognized that treatment with corticosteroids
will reduce the symptoms of chronic migraine; however this remedy is associated with long-term side effects.
Understanding the mechanisms involved in the expressional alterations may suggest novel ways to modify the
changes and indicate novel therapeutics. The results of the present work illustrate one way by which BoNT-A may
modify these expressional alterations.
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Background
Migraine is a common neurological disorder that afflicts
up to 16 % of the adult population in the Western coun-
tries [1]. It is characterized by episodic, often disabling
headache, associated with sensory, autonomic, central
nervous system (CNS) related and cognitive symptoms.
The current view is that migraine is a disorder in which
CNS dysfunction plays a pivotal role while various parts
of the trigeminal system are necessary for the expression
of peripheral symptoms and aspects of pain [2].
In a subgroup of migraine patients (1–2 %) the fre-
quency of migraine may expand over time to multiple
monthly attacks. Furthermore, these may progress to be
chronic (attacks > 15 days per month) and are often as-
sociated with medication overuse [3]. These patients are
very difficult to treat. Onabotulinumtoxin type A
(BoNT-A) has shown efficacy in the treatment of
chronic migraine [4–6], however its mechanism of ac-
tion remains in this relation elusive.
The effect of BoNT-A at the neuromuscular junction
is well demonstrated [7]. The C-terminal of the toxin
binds to the motor neuron and mediates endocytosis of
the toxin [8]. Within the vesicle of the motor endplate it
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cleaves the vesicular docking protein SNAP-25, which
leads to inhibition of acetylcholine storing vesicles dock-
ing on the presynaptic membrane and thus reduces
acetylcholine release [8]. The potential of BoNT-A in
treatment of migraine was suggested 15 years ago and
observed in conjunction with cosmetic treatments [9].
Since then several suggestions to explain the antimi-
graine effect has appeared. The most obvious would be
reduction in proprioceptive signaling to the brainstem
but also decreased mechanical sensitivity of nociceptors
and inhibition of craniofacial muscle tone [10–12].
These mechanisms were further developed and BoNT-A
was suggested to interfere with expression of mechano-
sensitive ion channels on meningeal nociceptors [13].
The aim of the present study was designed to ask if
BoNT-A can interact directly on sensory mechanisms
in the trigeminal ganglion (TG) using an organ cul-
ture method [14–16]. With this method we can study
whole TG, and the interrelation between neurons and
satellite glial cells (SGC). The neuronal-glial signalling
in the TG might be of much relevance in migraine
and in particular in the chronification pathology that
develops in many patients [17]. During organ culture
there is an inflammation response elicited with increased
expression of cytokines and mitogen-activated protein
kinases (MAPK) [14–16]. We hypothesized that BoNT-
A might interfere with the expressional changes of the
induced inflammation, and, in addition, the expression
of SNAP-25 and the Botulinum toxin receptor element
(SV2), molecules observed in the TG.
Methods
Ten Sprague Dawley rats (male, 200–250 g) were anesthe-
tized with CO2 and decapitated. Right and left TG were
removed and either used directly for experiments (fresh),
or incubated in Dulbecco’s modified Eagle’s medium
(DMEM; Gibco, Invitrogen, Carlsbad, CA, USA) supple-
mented with penicillin (100 U ml−1), streptomycin
(100 μg mL−1) and amphotericin B (0.25 μg mL−1) for
24 hours at 37 °C in humidified 5 % CO2 in air (for details
on the method see Tajti et al.) [15]. Prior to start of the in-
cubation the MEK1/2 inhibitor U0126 (LC laboratories,
Boston, MA, USA) 10 μM, BoNT-A (3 units/mL, ALLER-
GAN) or an equal volume of NaCl (vehicle) was added.
Incubation with the different substances was repeated 5–7
times. The experimental procedures were approved by the
University Animal Ethics Commtttee (M43-07).
TG (either fresh or after 24 hours of incubation) were
fixated in 4 % paraformaldehyde (Sigma, St Louis, USA) in
phosphate buffered saline (PBS) for 2–4 hours. After
fixation TG were cryoprotected using 10 % and 25 %
sucrose (Sigma) in Sorensen’s phosphate buffer. Subse-
quently, the specimens were embedded in gelatin medium
(30 % egg albumin, 3 % gelatin, Sigma), cryosectioned at
12 μm and stored at −20 °C until use.
Sections were thawed in room temperature, then rehy-
drated in PBS containing 0.25 % Triton X-100 (PBS-T;
Sigma) for 15 minutes. Sections were incubated with pri-
mary antibodies in PBS-T, containing 1 % bovine serum al-
bumin (BSA; Sigma), overnight in +4 °C. After incubation
with the primary antibody, sections were equilibrated to
room temperature, rinsed in PBS-T for 2×15 min, followed
by incubation with the secondary antibody for 1 hour in a
dark room at room temperature (for details on antibodies,
see Table 1). Sections were washed with PBST 2×15 min
and mounted with anti-fading mounting medium (Vecta-
shield, Vector Laboratories, Burlingame, CA, USA). Omis-
sion of the primary antibody served as negative control.
The immune-stainings were repeated 3–5 times. For gen-
eral morphology evaluation, sections were stained in
hematoxylin-eosin (Htx, Sigma).
Sections were examined and images were obtained
using light- and epifluorescence microscope (Nikon 80i,
Tokyo, Japan) equipped with a scanning stage for up-
right microscope (Märzhäuser, Germany) with travel
range X/Y 75 × 50 mm automatic adjustment of the Z-
axis, and coupled to a Nikon DS-2 MV camera. This en-
abled us to take large images of TG, with high reso-
lution. Images were taken using NIS basic research
software (Nikon, Japan). We estimated the number of
immunoreactive cells and the intensity in these images;
however, the detailed distribution was analyzed in regu-
lar images in 20× and 40× magnification. In addition, as
a complement to the analysis, fluorescence intensity was
measured in three sections of CGRP, IL-1β and SNAP-
25 stainings, since these showed neuronal immunoreac-
tivity which could be measured. Mean intensity and SD
were calculated. In iNOS and SV2-A stainings, the im-
munoreactivity was confined to the SGCs and could
thereby not be used in fluorescence intensity measure-
ments. Statistically, one-way ANOVA analysis and
Bonferroni’s multiple comparison test were used. P < 0.05
was considered as statistically significant.
Results
Morphology
The morphology of the TG was evaluated following
Htx staining (Fig. 1). Neurons of different size were
Table 1 Details on primary antibodies used for
immunohistochemistry
Name Host Dilution Supplier
iNOS Rabbit 1:200 Abcam; Cambridge, UK
IL1β Rabbit 1:400 Abcam; Cambridge, UK
SNAP-25 Rabbit 1:100 Sigma-Aldrich, St. Louis, MO, USA
SV2-A Rabbit 1:1000 Abcam; Cambridge, UK
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firmly enveloped by SGCs, demonstrating the close
interaction between the neurons and the glial cells.
The neurons contained a large pale nucleus and a vis-
ible nucleolus, and the SGCs displayed a slender,
slightly condensed nucleus.
In the specimens that underwent incubation during
24 hours, a similar morphology between the three
groups was observed: neurons with both condensed
cytoplasm and nuclei, and enlarged rounded SGCs
with highly condensed nuclei. Moreover, in groups
treated with U0126 or BoNT-A, the neurons were
often found in a vacuole indicating cell shrinkage and
SGC detachment.
Fresh TG
In the fresh TG, we observed both CGRP positive and
negative neurons (Fig. 2a). The CGRP immunoreactivity
was confined to the cytoplasm in a granular pattern,
resembling staining of the endoplasmatic reticulum. In
Fig. 1 Hematoxylin-Eosin staining. The column to the left shows the trigeminal ganglion in a fresh rat. The neurons were firmly enveloped by the
SGC (arrows), demonstrating the close interaction between the neurons and glial cells. In comparison to a neuron, which contained a large pale
nucleus and a visible nucleolus, the SGCs displayed a slender, slightly condensed nucleus. In the specimens that underwent incubation during
24 hrs, a similar morphology between the three groups was found: neurons with both condensed cytoplasm and nuclei, and enlarged rounded
SGCs with highly condensed nuclei (arrows). In groups incubated with U0126 or BoNT-A, the neurons were often found in a vacuole indicating
SGC detachment
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Fig. 2 CGRP immunohistochemistry. a Fresh TG contained both CGRP positive and negative neurons. The immunoreactivity was confined
to the cytoplasm in a granular pattern, resembling staining of the endoplasmatic reticulum, and in some of the fibers. In TG incubated in
medium containing saline, the number of neurons immunoreactive to CGRP seemed to be increased. The immunoreactivity was often
spread in a granular matter in the entire cytoplasm as observed in the fresh TG. In the specimens incubated with U0126 or BoNT-A, the
number of positive neurons increased and the immunoreactivity was found in the entire cytoplasm in almost all neurons. b To illustrate
the microscopical findings, fluorescence intensity measurements were performed. The results confirm these findings; a tendency of intensity increase
after 24 hrs of incubation with NaCl, U0126 or BoNT-A. Negative column is the same as in SNAP-25 diagram since the same secondary antibody is used
in both experiments. Bars indicate SD
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addition, some of the nerve fibers seen in TG were
CGRP positive.
iNOS immunoreactivity was exclusively found in the
SGCs (Fig. 3), and IL-1β immunoreactivity in almost
all neurons, which appeared as granules in the cyto-
plasm (Fig. 4a).
Scattered cytoplasmatic SNAP-25 immunoreactive gran-
ules were found in most neurons (Fig. 5a) and SV2-A
immunoreactivity in the cytoplasm of SGCs (Fig. 6).
Vehicle incubation for 24 hrs
In the NaCl incubated group (vehicle group), we observed
no clear difference in CGRP immunoreactivity compared
to fresh TG; both CGRP immunoreactive and negative
neurons were observed (Fig. 2a). In addition, the granular
intracytoplasmatic CGRP immunoreactivity found in fresh
TG was found after 24 hours of incubation with NaCl.
Immunoreactive CGRP positive fibers were also observed.
The SCGs displayed increased iNOS immunoreactivity
compared to fresh TG (Fig. 3). As for the fresh speci-
mens, almost all neurons in the incubated groups dis-
played IL-1β immunoreactivity, which appeared as
granules in the cytoplasm (Fig. 4a).
Compared to the fresh specimens, there was increased
SNAP-25 immunoreactivity in the neurons in the NaCl in-
cubated group, to such an extent that it was difficult to
discern the distribution of immunoreactivity within the
neurons (Fig. 5a). We found no difference in SV2-A im-
munoreactivity between the fresh specimens and the incu-
bation group (Fig. 6), except for the rounded shape of the
SGCs appearing after 24 hours of incubation, as also was
seen in the Htx staining (Fig. 1).
Fig. 3 iNOS immunohistochemistry. In fresh animals, the iNOS immunoreactivity was exclusively found in the SGCs (arrow). In the saline group,
some neurons and neuronal nuclei in addition to the SGCs (arrows) displayed immunoreactivity. In the groups incubated with U0126 or BoNT-A
the immunoreactivity had returned to levels found in fresh TG
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Fig. 4 IL1β immunohistochemistry. a Almost all neurons in the fresh specimens displayed IL1β immunoreactivity, which appeared as granules in
the cytoplasm. This pattern was also found in the saline incubated groups. The groups incubated with U0126 or BoNT-A showed none or little
IL1β immunoreactivity. b Fluorescence intensity measurements confirmed these findings. Bars indicate SD
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Fig. 5 SNAP-25 immunohistochemistry. a Scattered cytoplasmatic SNAP-25 immunoreactive granules were found in most neurons in the fresh specimens.
The intensity of the staining in the incubated groups increased intensively, making it difficult to discern the distribution of immunoreactivity within the
neurons. b Fluorescence intensity measurements confirmed these findindings. Negative column is the same as in SNAP-25 diagram since the same
secondary antibody is used in both experiments. Bars indicate SD
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U0126 and BoNT-A incubation for 24 hrs
Compared to the fresh specimens, the number of CGRP
positive cells was clearly increased in the U0126 group.
This was more marked in the BoNT-A treated TG
(Fig. 2a). In addition the distribution of the immunore-
activity differed compared to fresh and saline groups; the
immunoreactivity was found in the entire cytoplasm in
almost all neurons compared to the granular pattern ob-
served in the other groups.
Compared to NaCl incubated group, iNOS immunore-
activity has returned to levels found in fresh TG (Fig. 3)
and IL-1β immunoreactivity has decreased compared to
fresh, or saline group (Fig. 4a).
The cytoplasmatic SNAP-25 immunoreactive granules
found in neurons in the fresh specimens were visible
again (after being hidden in the NaCl group by the high
intensity of the staining), even though the intensity was
considerably increased in the U0126 and BoNT-A
groups compared to fresh (Fig. 5a). No difference could
be seen in the SV2-A immunoreactivity between all the
groups examined (Fig. 6).
Fluorescence intensity measurements of CGRP, IL-1β
or SNAP-25 were performed on incubated specimens
(Figs. 2b, 4b, 5b). The intensity in the neurons was mea-
sured and the mean intensity was calculated. Statistically,
one-way ANOVA analysis and Bonferroni’s multiple
comparison test were used. The measurements con-
firmed the microscopical results and are presented in
the illustrations.
Major findings are illustrated schematically in Fig. 7.
Fig. 6 SV2-A immunohistochemistry. In all groups, including fresh, SV2-A immunoreactivity was confined to the cytoplasm of SGCs (arrows).
No difference was detected between the groups, except for the rounded shape of the SGCs appearing after 24 hrs of incubation
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Discussion
The present study was designed to examine isolated TG
neurons and SGCs during different organ culture condi-
tions as a method to illustrate possible expressional al-
terations of CGRP, iNOS, IL-1 β, SNAP-25 and SV2-A.
The underlying hypothesis is that chronic migraine is as-
sociated with inflammation in various parts of the tri-
geminal system and organ culture is a way to induce an
inflammatory response in the TG. The advantage of this
method is the study of neurons and SGCs in their nor-
mal habitat. We report that the studied molecules were
observed in fresh TG with a differential distribution.
Interestingly, organ culture co-incubated with the ve-
hicle NaCl of the TG for 24 hours resulted in enhanced
expression of CGRP and SNAP-25 in neurons, and iNOS
in SGCs. Co-incubation with U0126 and BoNT-A
retained the increased expression of SNAP-25, while it
decreased the IL-1 β immunoreactivity in neurons. The
iNOS expression in SGCs returned to levels observed in
fresh specimens. Moreover, we observed no alteration of
SV2-A expression in SGCs. However, the overall picture
is that both U0126 and BoNT-A have the ability to mod-
ify/reduce the expression of certain molecules in the TG.
CGRP was used to provide further in depth information
how and if this system are involved using our method.
Organ culture results in increased expression of CGRP
immunoreactivity in the TG neurons at 48 hours [14, 15],
but only slightly at 24 hours (present data). Although we
did not perform any detailed cell counting in the present
study, the localization resembles that described by Eftekhari
et al. (2010) [18].
iNOS is expressed by a wide variety of cell types, in-
cluding neurons and SGCs [19]. We show that iNOS is
expressed exclusively in SGCs of the TG. Increased
iNOS expression in glial cells is implicated in the eti-
ology of CNS diseases by causing inflammation and
cytotoxicity [20, 21]. Inflammatory stimuli, in our case
incubation for 24 hours with saline, revealed increased
expression of iNOS in SGCs as compared to non-
incubated TG. It has been demonstrated that there is in-
creased expression of iNOS in isolated cultured SGCs in
response to CGRP and this is mediated by activation of
the MAPKs ERK1/2, JNK and p38 [22]. In the present
study, we extended the findings to provide evidence that
co-incubation with U0126 or BoNT-A show the same
expression of iNOS as seen in fresh specimens; this
means that these treatments reduced the organ culture
induced increase in iNOS expression.
There is IL-1β immunoreactivity expressed in many neu-
rons in fresh TG. Co-incubation with saline did not change
this pattern of expression, however, the MEK1/2 inhibitor
U0126 and BoNT-A decreased the expression of IL-1β.
There is increasing evidence that proinflammatory cyto-
kines (IL-1 β, IL-6 and TNF-α) either are synthesized in the
central (CNS) or in the peripheral nervous system (PNS) by
resident cells, or imported by immune blood cells. These
are involved in several pathophysiological functions, includ-
ing an unexpected impact on synaptic transmission and
neuronal excitability. Targeting these cytokines, and related
signalling molecules, is considered a novel option for the
development of therapies in various CNS or PNS disorders
associated with an inflammatory component [23].
BoNTs is known to inhibit the release of excitatory
neurotransmitters from both motor and sensory neurons
by preventing vesicle fusion to cell membrane [24].
Under pathophysiological conditions, BoNTs prevent
neurotransmission from almost every type of neuron
suggesting common targets present in the majority of
neurons. BoNTs specifically and exclusively attack pre-
synaptic nerve terminals. The fusion of a secretory
vesicle with the cell membrane is a highly regulated
process with the formation of t-SNARE complex play-
ing a pivotal role. The light chain of BoNTs acts to
cleave SNAP-25, which inhibits synaptic exocytosis,
and therefore, disables neural transmission [25]. We
report that the level of expression of SNAP-25 in-
creased after incubation with BoNT-A, but also after
NaCl and U0126 incubation. This indicates accumula-
tion of SNAP-25 in the cytosol of the neurons, as a
suggestion regarding BoNT-A incubated TG, from
cleavage of SNAP-25 inhibiting exocytosis. However,
other mechanisms may be involved when it comes to
TG incubated with NaCl or U0126.
Fig. 7 Schematic drawings. The drawing demonstrates the major
immunohistochemical findings in neurons and SGCs. CGRP, IL1β and
SNAP-25 were mainly found in the neurons, and iNOS and SV2-A in
the SGCs. Arrows illustrate increase and decrease, respectively.
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Synaptic vesicles (SVs), present in all types of neu-
rons [26, 27], are secretory organelles of presynaptic
nerve terminals that accumulate high quantities of
neurotransmitters and secrete them by fusion with
the presynaptic plasma membrane. BoNT-A may
enter neurons by binding to synaptic vesicle protein
SV2 (isoforms A, B or/and C) [18]. The details of the
BoNT-A binding to SV2 has been clarified in hippo-
campus from knockout mice, demonstrating that
those that lacked the isoforms displayed reduced sen-
sitivity to BoNT-A. It was concluded that SV2 acts as
the protein receptor for BoNT-A [19]. We showed
that the SV2-A isoform is expressed in the SGCs of
rat TG, but not in the neurons. This would point to-
wards these cells as a possible site for a putative ac-
tion of BoNT-A.
The SGCs surround the TG neurons like a pearl neck-
lace, outnumber the neurons in a 10:1 manner, and are
joined by gap junctions [20, 28]. The space between the
SGCs and the neurons is 20 nm, which allows for an effect-
ive control of the extracellular environment by both neu-
rons and SGCs [20]. The role of the SGCs in the function
of the trigeminovascular system is poorly known and has
by and large received little attention over the years [20]. In
previous work, we observed that the SGCs stored CGRP
receptor components (RAMP1, CLR) [18]. In the present
study we demonstrate the presence of the inflammation
marker iNOS. Vast evidence exists for interaction between
the SGCs and the TG neurons. Hence these may be acti-
vated via peripheral nociceptors such as those within the
dura mater (20, 21) and from the temporomandibular joint
(TMJ) [23, 29], as well as from central connections in the
trigeminal nucleus caudalis (TNC) [13, 30].
The organ culture method has been used in various
reports from our laboratory [14–16]. It has been shown
that the method could be used to investigate inflamma-
tory events and neuropeptide expression in the TG. In
the present study we show that 24 hours of incubation
results in condensed nuclear chromatin and compacted
cytoplasm in neurons, and enlarged rounded SGCs
with highly condensed nuclear chromatin. Moreover, in
groups treated with U0126 or BoNT-A, the neurons
were often found in a vacuole indicating cell shrinkage
and SGC detachment. The impact of these findings in
correlation with the expressional alterations of CGRP,
iNOS, IL-1 β, SNAP-25 and SV2-4 can only be specu-
lated upon. Pannese (2010) highlighted the striking
morphological changes that SGCs undergo after nerve
injury, which includes hypertrophy and formation of
bridges with other SGCs, which contain numerous
newly formed gap junctions [31]. Obviously, SGCs can
sense injury-related changes in the neurons, which
might have influenced some of the expressional alter-
ations demonstrated here.
Recently, we asked if a chronic inflammation elicited
with injection into the TMJ of CFA [32] or CGRP [33], of
CFA on the dura mater (Lukács M, Haanes KA, Majláth
Z, Tajti J, Vécsei L, Warfvinge K, Edvinsson L. Exposure of
the rat dura mater to inflammatory soup or Complete
Freund’s Adjuvant induces an inflammatory response in
the rat trigeminal ganglion.) might result in altered ex-
pression of various markers in the TG. We feel it is of par-
ticular importance to maintain the cellular organization
because activation of trigeminal neurons leads to changes
in adjacent glia that may involve communication through
gap junctions and paracrine signaling [17]. The animals
were followed for a week and during this time there was a
successive increase in inflammation mediators in SGCs
and neurons. Interestingly, this enhanced expression could
be modified by mitogen-activated protein kinase (MAPK)
inhibition in vivo or modified by interacting with the glu-
tamatergic system. In the present method of organ culture
we found activation of some of these molecules. The
MAPK inhibitor U0126 could modify the expression of
CGRP and IL-β. On the other hand the inhibition of a sin-
gle molecule such as CGRP receptor telcagepant did not
change the expression (data not shown). Interestingly,
BoNT-A had the same effect as for U0126.
Conclusion
We hypothesize that chronic migraine might be associated
with some degree of inflammation in the TG that could in-
volve both neurons and SGCs. It is a clinically well recog-
nized that treatment with corticosteroids will reduce the
symptoms of chronic migraine; however this remedy is as-
sociated with long-term side effects. Understanding the
mechanisms involved in the expressional alterations in the
trigeminal system may suggest novel ways to modify the
changes and indicate novel therapeutics. The results of the
present work illustrate one way by which BoNT-A could
modify these expressional alterations in the sensory TG.
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